Analysis set (n)

Safety analysis set (28)

Efficacy analysis set (24)

Diagnosis, n (%)

NTG

16 (57.1%)

14 (58.3%)

POAG

11 (39.3%)

9 (37.5%)

OH

1 (3.6%)

1 (4.2%)

Sex, n (%)

Male

11 (39.3%)

8 (33.3%)

Female

17 (60.7%)

16 (66.7%)

Age (year)

Minimum-Maximum

41.0 - 84.0

41.0 - 84.0

Mean ± standard deviation

66.6 ± 13.1

65.7 ± 13.6

Ocular complication, n (%)

Positive

8 (28.6%)

6 (25.0%)

Negative

20 (71.4%)

18 (75.0%)

Concomitant glaucoma ophthalmic solution, n (%)

Dorzolamide

4 (14.3%)

4 (16.7%)

Brinzolamide

17 (60.7%)

14 (58.3%)

Brimonidine

6 (21.4%)

5 (20.8%)

Bunazosin

1 (3.6%)

1 (4.2%)